INTRON A is indicated for the treatment of high tumour burden Follicular Lymphoma as adjunct to appropriate combination induction chemotherapy such as a CHOP-like regimen.
Follicular Lymphoma (FL)
1. Approved Labelling
Intron A is indicated for the treatment of high tumor burden Follicular Lymphoma as adjunct to appropriate combination induction chemotherapy such as a CHOP-like regimen. High tumor burden is defined as having at least one of the following: bulky tumor mass (> 7 cm), involvement of three or more nodal sites (each > 3 cm), systemic symptoms (weight loss > 10%, pyrexia > 38°C for more than 8 days, or nocturnal sweats), splenomegaly beyond the umbilicus, major organ obstruction or compression syndrome, orbital or epidural involvement, serous effusion, or leukemia.
2. Treatment Regimen
Treatment must be initiated by a physician experienced in the management of the disease.
Adjunctively with chemotherapy, interferon alpha 2b may be administered subcutaneously, at a dose of 5 million IU three times a week (every other day) for a duration of 18 months. CHOP-like regimens are advised, but clinical experience is available only with CHVP (combination of cyclophosphamide, doxorubicin, teniposide and prednisolone).
Please see section 4.4 of the SmPC.
All content on this site is intended for healthcare professionals only. If you are a patient or carer, please visit the Lymphoma Coalition.